The company named Merck KGaA’s Belen Garijo as the successor to Paul Hudson. The change follows a string of clinical setbacks ...

The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent ...

Sanofi abruptly replaced Chief Executive Officer Paul Hudson after a massive research spending boost failed to deliver rapid results, appointing its first female leader, Merck KGaA’s Belén Garijo.

Sanofi is replacing Paul Hudson as CEO, amid questions about which medicines will drive the company's growth in the future.

Sanofi’s Board of Directors announced Belén Garijo as the company’s next CEO following the move to not renew the tenure of ...

BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity ...

Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Houman Ashrafian, MD, PhDHead of Research and Development, ...

Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing ...

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of ...

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered ...